{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for glycerol root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Possibly Marketed Outside US
Source:
NDA209401
(2017)
Source URL:
First approved in 2017
Source:
NDA209401
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
ABELCET
Source URL:
First approved in 2010
Source:
M018
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL- is a component of ABELCET® (Amphotericin B Lipid Complex Injection). It consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine and l-α-dimyristoylphosphatidylglycerol, are present in a 7:3 molar ratio. ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on the open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy.
Status:
Possibly Marketed Outside US
Source:
LUMASON
Source URL:
First approved in 1999
Source:
NDA021041
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
1,2-Dipalmitoyl-sn-glycero-3-phosphorylglycerol sodium salt (DPPG) is phosphorylglycerol acylated with palmitic acid, that can be used for the preparation of liposomes with negatively charged hydrophilic head groups.
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2007)
Source URL:
First approved in 2007
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333B
(2021)
Source URL:
First approved in 1984
Source:
NADA128409
Source URL:
Class:
MIXTURE
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
